July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Endophthalmitis Rates Following Anti-VEGF Intravitreal Injections with 10% Betadine
Author Affiliations & Notes
  • Amber Hoang
    Ophthalmology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
  • Keegan Harkins
    Ophthalmology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
  • Maria Manuela Gutierrez Velez
    Wake Forest School of Medicine, North Carolina, United States
  • Barlett Hayes II
    Ophthalmology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
  • Margaret Greven
    Ophthalmology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
  • Craig M Greven
    Ophthalmology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
  • Rajiv Shah
    Ophthalmology, Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
  • Footnotes
    Commercial Relationships   Amber Hoang, None; Keegan Harkins, None; Maria Manuela Gutierrez Velez, None; Barlett Hayes II, None; Margaret Greven, None; Craig Greven, None; Rajiv Shah, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2032. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Amber Hoang, Keegan Harkins, Maria Manuela Gutierrez Velez, Barlett Hayes II, Margaret Greven, Craig M Greven, Rajiv Shah; Endophthalmitis Rates Following Anti-VEGF Intravitreal Injections with 10% Betadine. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2032. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Development of endophthalmitis is one of the most devastating complications of intravitreal injections leading to loss of vision and the eye. To date, there is no study in the literature to assess the effectiveness of 10% betadine in the prevention of endophthalmitis. We performed a retrospective, observational cohort study to evaluate the rate of endophthalmitis with 10% betadine compared to published rates of endophthalmitis using current standard of care 5% betadine.

Methods : A retrospective, observational cohort study review of patients developing post-intravitreal injection endophthalmitis at Wake Forest Baptist Eye Center using 10% betadine. ICD-10 procedure codes for intravitreal injections of “bevacizumab”, “ranibizumab”, “aflibercept” were searched for the time frame January 2001 – November 2018. Of these charts, codes for “endophthalmitis”, “corneal erosion”, and “corneal abrasion” were searched. Cases of endogenous endophthalmitis, uveitis, intraocular steroids, and immunosuppression were excluded. Primary outcome is development of endophthalmitis post-intravitreal injections with 10% betadine. Secondary outcome is development of side effects of corneal toxicity with 10% betadine. Statistical analysis was performed and compared to published rates of endophthalmitis using current standard of care 5% betadine.

Results : A total of 41,314 anti-VEGF intravitreal injections (4,315 patients) in the 10% betadine group were included, from which 2 cases of endophthalmitis were identified. Cultures demonstrated pasteurella multocida and coagulase-negative staphylococci. Current published rates of endophthalmitis after intravitreal injections with 5% betadine range from 0.02% to 0.08%. The rate of post-intravitreal endophthalmitis in the 10% betadine group is 0.0048%, which is statistically significantly lower than in the 5% betadine group (p<0.05, chi-squared test). Corneal toxicity was not evidenced in our study; however, increased patient complaints of irritation post-injection were noted in the chart review.

Conclusions : Our results are consistent with our hypothesis that using 10% betadine may lower rates of post-intravitreal endophthalmitis compared to 5% betadine and should be considered as a reasonable alternative to the current standard of care.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×